PL3256580T3 - Proteaza cysteinowa - Google Patents
Proteaza cysteinowaInfo
- Publication number
- PL3256580T3 PL3256580T3 PL16707653.8T PL16707653T PL3256580T3 PL 3256580 T3 PL3256580 T3 PL 3256580T3 PL 16707653 T PL16707653 T PL 16707653T PL 3256580 T3 PL3256580 T3 PL 3256580T3
- Authority
- PL
- Poland
- Prior art keywords
- cysteine protease
- cysteine
- protease
- Prior art date
Links
- 102000005927 Cysteine Proteases Human genes 0.000 title 1
- 108010005843 Cysteine Proteases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502306A GB201502306D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053052 WO2016128558A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3256580T3 true PL3256580T3 (pl) | 2022-11-28 |
Family
ID=52781456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16707653.8T PL3256580T3 (pl) | 2015-02-12 | 2016-02-12 | Proteaza cysteinowa |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10696959B2 (OSRAM) |
| EP (2) | EP3256580B1 (OSRAM) |
| JP (1) | JP6961486B2 (OSRAM) |
| KR (1) | KR102524613B1 (OSRAM) |
| CN (2) | CN114231512B (OSRAM) |
| AU (2) | AU2016217800B2 (OSRAM) |
| BR (1) | BR112017017284A2 (OSRAM) |
| CA (1) | CA2976003A1 (OSRAM) |
| CL (1) | CL2017002065A1 (OSRAM) |
| CO (1) | CO2017009061A2 (OSRAM) |
| DK (1) | DK3256580T3 (OSRAM) |
| EA (1) | EA035130B1 (OSRAM) |
| ES (1) | ES2927234T3 (OSRAM) |
| GB (1) | GB201502306D0 (OSRAM) |
| IL (1) | IL253938B (OSRAM) |
| LT (1) | LT3256580T (OSRAM) |
| MX (1) | MX390806B (OSRAM) |
| MY (1) | MY188696A (OSRAM) |
| PL (1) | PL3256580T3 (OSRAM) |
| PT (1) | PT3256580T (OSRAM) |
| SG (1) | SG11201706346QA (OSRAM) |
| WO (1) | WO2016128558A1 (OSRAM) |
| ZA (1) | ZA201705113B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| SG11202009451VA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
| EP4038194A1 (en) | 2019-10-04 | 2022-08-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| US11186625B2 (en) * | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| CA3164714A1 (en) | 2020-02-14 | 2021-08-19 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating cdkl5 deficiency disorder |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| GB202003129D0 (en) * | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| CN115066261A (zh) | 2020-06-05 | 2022-09-16 | 上海宝济药业有限公司 | 一种酶和病毒的药物组合及其应用 |
| JP2023532219A (ja) * | 2020-06-18 | 2023-07-27 | 上海宝済薬業有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの突然変異体 |
| CN116745409A (zh) | 2020-08-19 | 2023-09-12 | 萨雷普塔治疗公司 | 用于治疗雷特综合征的腺相关病毒载体 |
| JP2023545731A (ja) | 2020-10-07 | 2023-10-31 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| US20250019721A1 (en) | 2021-08-11 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| AU2022385450A1 (en) | 2021-11-15 | 2024-06-13 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| CN118382456A (zh) | 2021-12-16 | 2024-07-23 | 上海宝济药业股份有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
| CN118382454B (zh) * | 2021-12-22 | 2025-10-31 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体的用途 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833B (zh) * | 2022-11-08 | 2024-08-16 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| CN120677180A (zh) | 2022-11-18 | 2025-09-19 | 赛斯米克治疗公司 | Fc融合分子及其用途 |
| US12129499B2 (en) | 2023-01-06 | 2024-10-29 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025072144A1 (en) * | 2023-09-27 | 2025-04-03 | Osprey Biopharmaceuticals, Inc. | Polypeptides having human igg cleavage activity |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| US7595057B2 (en) | 2000-12-21 | 2009-09-29 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| AU2003284441A1 (en) * | 2002-11-29 | 2004-06-23 | Morinaga Milk Industry Co., Ltd. | Protease inhibitor |
| DE602004022923D1 (de) * | 2003-03-04 | 2009-10-15 | Intercell Ag | Streptococcus pyogenes antigene |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| EP1901773B1 (en) * | 2005-06-09 | 2012-03-07 | Hansa Medical AB | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| US7544577B2 (en) * | 2005-08-26 | 2009-06-09 | International Business Machines Corporation | Mobility enhancement in SiGe heterojunction bipolar transistors |
| DK2190984T3 (da) | 2007-09-14 | 2013-12-02 | Genovis Ab | Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG |
| JP2011506433A (ja) | 2007-12-13 | 2011-03-03 | インターバック アーベー | 改変された免疫組成物 |
| WO2009080278A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Stability testing of antibodies |
| CN102308216B (zh) * | 2009-02-09 | 2014-07-09 | 罗切格利卡特公司 | 免疫球蛋白糖基化模式分析 |
| ES2948841T3 (es) | 2010-05-26 | 2023-09-20 | Intervacc Ab | Vacuna contra infecciones estreptocócicas basada en proteínas de fusión recombinantes |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| CN103214549B (zh) * | 2013-01-15 | 2015-08-05 | 珠海市丽珠单抗生物技术有限公司 | 一种还原免疫球蛋白的方法及其试剂盒 |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
-
2015
- 2015-02-12 GB GB201502306A patent/GB201502306D0/en not_active Ceased
-
2016
- 2016-02-12 EP EP16707653.8A patent/EP3256580B1/en active Active
- 2016-02-12 JP JP2017542896A patent/JP6961486B2/ja active Active
- 2016-02-12 CN CN202111557859.9A patent/CN114231512B/zh active Active
- 2016-02-12 PL PL16707653.8T patent/PL3256580T3/pl unknown
- 2016-02-12 MY MYPI2017001124A patent/MY188696A/en unknown
- 2016-02-12 SG SG11201706346QA patent/SG11201706346QA/en unknown
- 2016-02-12 EA EA201791773A patent/EA035130B1/ru not_active IP Right Cessation
- 2016-02-12 KR KR1020177025560A patent/KR102524613B1/ko active Active
- 2016-02-12 DK DK16707653.8T patent/DK3256580T3/da active
- 2016-02-12 AU AU2016217800A patent/AU2016217800B2/en active Active
- 2016-02-12 US US15/550,309 patent/US10696959B2/en active Active
- 2016-02-12 CA CA2976003A patent/CA2976003A1/en active Pending
- 2016-02-12 BR BR112017017284A patent/BR112017017284A2/pt not_active Application Discontinuation
- 2016-02-12 MX MX2017010390A patent/MX390806B/es unknown
- 2016-02-12 WO PCT/EP2016/053052 patent/WO2016128558A1/en not_active Ceased
- 2016-02-12 ES ES16707653T patent/ES2927234T3/es active Active
- 2016-02-12 PT PT167076538T patent/PT3256580T/pt unknown
- 2016-02-12 EP EP22174919.5A patent/EP4108768A1/en active Pending
- 2016-02-12 CN CN201680021601.8A patent/CN107532156A/zh active Pending
- 2016-02-12 LT LTEPPCT/EP2016/053052T patent/LT3256580T/lt unknown
-
2017
- 2017-07-27 ZA ZA2017/05113A patent/ZA201705113B/en unknown
- 2017-08-10 IL IL253938A patent/IL253938B/en active IP Right Grant
- 2017-08-11 CL CL2017002065A patent/CL2017002065A1/es unknown
- 2017-09-04 CO CONC2017/0009061A patent/CO2017009061A2/es unknown
-
2020
- 2020-05-20 US US16/879,324 patent/US11214784B2/en active Active
-
2021
- 2021-11-11 AU AU2021266293A patent/AU2021266293B2/en active Active
- 2021-12-14 US US17/644,315 patent/US11667905B2/en active Active
-
2023
- 2023-05-16 US US18/318,455 patent/US12359183B2/en active Active
-
2025
- 2025-06-09 US US19/232,657 patent/US20250304937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253939A0 (en) | cysteine protease | |
| IL253938A0 (en) | cysteine protease | |
| AU364424S (en) | Watchcase | |
| AU364423S (en) | Watchcase | |
| DK3298030T5 (en) | Anti-cancerfusionspolypeptid | |
| DK3380145T3 (en) | Injektionsapparat | |
| IL253635A0 (en) | Cyclopropanebenzofuranyl pyridopyrazinedione type compounds | |
| DK3324768T3 (en) | Tørdragt | |
| PL3458583T3 (pl) | Proteazy o polepszonej skuteczności | |
| GB201506316D0 (en) | Novel peptide | |
| GB201417288D0 (en) | Cysteine labelling | |
| GB201513444D0 (en) | Peptoid | |
| EP3104705A4 (en) | Cathepsin cysteine protease inhibitors | |
| GB201502316D0 (en) | Bitcon technology | |
| GB201502073D0 (en) | HDEG technology | |
| HUP1500342A2 (en) | Cylinder-head | |
| GB201506360D0 (en) | Novel peptide | |
| GB201516577D0 (en) | Project P | |
| GB201415235D0 (en) | Trans-locating peptide | |
| AU362754S (en) | Playsuit | |
| GB201505170D0 (en) | Concept 36A | |
| GB201404910D0 (en) | Trans-locating peptide | |
| GB201507783D0 (en) | E-calendar | |
| GB201507770D0 (en) | Rebarmat | |
| GB201507213D0 (en) | Immagine |